@article {7642,
	title = {Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: A Hellenic Cooperative Oncology Group study},
	journal = {Pharmacogenomics},
	volume = {13},
	year = {2012},
	note = {Cited By :1Export Date: 21 February 2017},
	month = {2012},
	pages = {1595 - 1607},
	abstract = {Aim: The association between two polymorphisms of ERCC1 and treatment outcomes after platinum-based chemotherapy in patients with advanced urothelial cancer (UC) was examined. Materials \& methods: Genotyping of 19007C>T and 8092C>A polymorphisms was determined by PCR amplification and RFLP in 113 advanced UC patients, treated with platinum-based chemotherapy. Results: Seventy eight patients (69\%) were carriers of the 19007T polymorphic allele: 51 (45\%) heterozygotes and 27 (24\%) homozygotes. Fifty three (47\%) patients were carriers of the 8092A polymorphic allele: the frequencies of C/A and A/A genotypes were 37\% and 10\%, respectively. The T/T genotype was independently associated with prolonged median cancer-specific survival (not-reached vs 14.8 months; p = 0.026). There was no interaction between T/T or any other genotype with the type of platinum derivative (cisplatin/carboplatin). Conclusion: 19007C>T, especially in its homozygotic state, but not 8092C>A polymorphism, could be a useful prognostic marker in advanced UC treated with platinum-based chemotherapy. Original submitted 17 July 2012; Revision submitted 21 September 201. {\textcopyright} 2012 Future Medicine Ltd.},
	keywords = {Cisplatin, human ERCC1 gene, nucleotide excision repair, single-nucleotide polymorphism, urothelial cancer},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84869022939\&doi=10.2217\%2fpgs.12.162\&partnerID=40\&md5=84355093aae9fa6aa8f4ee5eb5ba524f},
	author = {Nikitas, N. and Karadimou, A. and Tsitoura, E. and Soupos, N. and Tsiatas, M. and Karavasilis, V. and Pectasides, D. and N. Pavlidis and Chrisofos, M. and Adamakis, I. and Murray, S. and Fountzilas, G. and Dimopoulos, M.-A. and Bamias, A.}
}
